Novos general counsel John Kuckelman told CNBC it may have been accurate for Lilly to boast about Zepbounds greater efficacy before the 7.2 milligram dose of Wegovy became available, but it is no longer accurate to say that. Novos suit says Lilly acknowledges a higher dose of Wegovy in a brief footnote in the television ad, but it says the footnote is ambiguous, confusing, virtually illegible, and wholly inadequate. key background Novo Nordisk and Eli Lilly, chief rivals in the booming GLP-1 industry, have struggled for dominance over the obesity medication market, with Novos market share slipping from an early lead
Hands Off Your Face Your hands collect oils and bacteria throughout the day
When clinically appropriate, our Carmel providers may prescribe GLP-1 medications including semaglutide and tirzepatide as part of a physician-supervised weight loss program
Available online at: (Accessed September 1, 2025)
20-22 However, a reduction in the progression to end-stage kidney disease is yet to be demonstrated
